Healthcare / BiotechnologyParis
$0.24
+0.07 (+41.49%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF n/d · quality 62.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$2M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-8.5%
↓Gross Margin
40.0%
↓Debt/Equity
0.56
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2023 · 2 años de histórico normalizado
Revenue CAGR
+5.2%
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue $12.5M · net income $-171399.0 · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $12.5M | $12.5M | $13.2M | $11.3M |
| Net Income | $-171399.00 | $-171399.00 | $-3507.00 | $15407.00 |
| EBITDA | $-52505.00 | $-52505.00 | $69962.00 | $20182.00 |
| EPS | -0.03 | -0.03 | -0.00 | 0.00 |
| Gross Margin | 40.0% | 40.0% | 36.0% | 36.6% |
| Operating Margin | -0.9% | -0.9% | -0.5% | -0.6% |
| Net Margin | -1.4% | -1.4% | -0.0% | 0.1% |
| Balance Sheet | ||||
| Debt/Equity | 0.56 | 0.56 | 0.77 | 0.89 |
| Current Ratio | 0.95 | 0.95 | — | — |
| Returns | ||||
| ROE | -8.5% | -8.5% | -0.2% | 0.7% |
| Valuation | ||||
| P/E | — | — | — | 519.76 |
| EV/EBITDA | — | — | 117.58 | 348.08 |
| P/B | 0.78 | 0.78 | 4.13 | 3.66 |
| Growth & Yield | ||||
| Revenue Growth | -4.8% | -4.8% | 16.3% | — |
| EPS Growth | -5073.9% | -5073.9% | -122.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-54.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.00 → -0.03
Residual
-54.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.